SF3B1 Mutations Increase DCAF16 Expression to Create Targeted Therapeutic Vulnerability

Targeting Splicing Factor Mutations in Hematologic Malignancies

Somatic mutations in the splicing factor SF3B1 are among the most frequent genetic alterations in chronic lymphocytic leukemia and myelodysplastic syndromes, where they serve as independent markers of poor clinical prognosis [1, 2, 3]. In a meta-analysis of 24,060 patients, these mutations were associated with a hazard ratio of 1.68 for overall survival [1]. These alterations disrupt alternative splicing, the regulatory process that allows a single gene to produce multiple protein isoforms, leading to the production of dysfunctional proteins that drive tumor proliferation and immune evasion [4, 5, 6]. While clinical management relies on genomic profiling to stratify risk, patients with these recurrent mutations often face relapsed or refractory disease; in such cases, multiple concurrent mutations are associated with a median progression-free survival of only 12 months [7, 8]. A new study now details how these splicing errors affect noncoding regions, which are DNA sequences that do not encode proteins but regulate their production, to create specific therapeutic vulnerabilities [9].

Noncoding Splicing Errors Drive Oncogenesis

Oncogenic mutations of SF3B1 are frequently identified in myeloid cancers, chronic lymphocytic leukemia, and specific solid tumors, where they act as primary drivers of malignancy. Historically, the mechanistic understanding of how these mutations promote oncogenesis has focused on the stereotyped missplicing of messenger RNA protein coding sequences, which are the specific segments of genetic material that provide the direct instructions for building proteins. These splicing errors in critical genes, including MAP3K7, BRD9, and ABCB7, typically result in a loss of function. In clinical terms, this means the proteins these genes produce are either truncated or degraded, depriving the cell of tumor-suppressive signals and contributing to the overall pathogenesis of the cancer. To expand beyond these known coding errors, researchers conducted a systematic analysis of how mutant SF3B1 affects the noncoding regions of messenger RNA transcripts, the portions of the genetic message that do not code for proteins but instead regulate how much protein is produced and when. This investigation utilized a broad dataset encompassing both established cell lines and primary patient specimens to ensure the findings were representative of actual clinical disease. The study identified numerous and highly reproducible splicing alterations within these noncoding regions across multiple disease types. By shifting the focus to these regulatory segments, the authors demonstrated that SF3B1 mutations do more than just disable proteins; they fundamentally alter the regulatory landscape of the transcriptome, the complete set of all RNA molecules expressed in a cell.

Gain-of-Function Protein Expression via UTR Alterations

The researchers focused their investigation on a specific target gene, DCAF16, which exhibited multiple complex mutation-induced alterations within its 5' and 3' untranslated regions (UTRs). These UTRs represent the regulatory segments at the beginning and end of a messenger RNA transcript that do not code for proteins themselves but instead dictate the stability and translation of the genetic message. While previous studies of SF3B1 mutations have largely documented splicing errors that result in protein loss, the specific alterations identified in the 5' and 3' UTRs of DCAF16 were mechanistically associated with increased DCAF16 protein levels in SF3B1-mutant cells. This finding is clinically significant as it represents the first time oncogenic SF3B1 has been found to increase levels of a target protein in a gain-of-function manner, diverging from the established pattern of tumor-suppressor inactivation. In the cellular environment, DCAF16 serves as a substrate recognition adapter for the DDB1/CUL4 E3 ubiquitin ligase complex. In this capacity, DCAF16 acts as a specialized protein that helps the cell's internal waste-disposal machinery identify and tag specific proteins for degradation. By driving the overexpression of this adapter through noncoding splicing errors, SF3B1 mutations do not merely disable cellular pathways but instead create a distinct biochemical state characterized by an abundance of this specific recognition protein. This shift provides a potential therapeutic opening, as the elevated levels of DCAF16 in SF3B1-mutant cells may be leveraged to direct the degradation of oncogenic targets that are otherwise difficult to reach with standard inhibitors.

Selective Lethality Using Protein Degraders

To exploit the elevated levels of DCAF16 in malignant cells, the researchers developed novel protein degrader small molecules designed to coopt DCAF16 as a recruitment mechanism. These molecules function by tethering DCAF16 to BRD4, a bromodomain protein that frequently drives oncogenic transcription and cancer cell proliferation. By forcing this proximity, the small molecules induce DCAF16 to recognize BRD4 as a neosubstrate, a protein not normally targeted by a specific ligase, effectively hijacking the cell's ubiquitin ligase complex to tag BRD4 for proteasomal degradation. This biochemical strategy turns the mutation-induced gain of DCAF16 protein into a liability for the cancer cell, utilizing the cell's own overexpressed machinery to eliminate a critical growth factor. In preclinical testing, these protein degraders demonstrated preferential selectivity for SF3B1-mutant cancers and primary patient specimens of chronic lymphocytic leukemia. The study confirmed that this therapeutic selectivity is directly driven by the increased DCAF16 protein levels present in SF3B1-mutant cells compared to wild-type cells. Because the efficacy of the degrader is dependent on the concentration of the DCAF16 adapter, the treatment is significantly more potent in cells harboring the splicing mutation. This dysregulation of transcript untranslated regions by mutant SF3B1 reveals a viable therapeutic strategy for treating myeloid and lymphoid neoplasms, as it allows for the selective targeting of malignant cells while potentially sparing healthy tissues that maintain lower, baseline levels of DCAF16.

References

1. Huang L, Shi X, Tang N, Liu J, Liang Y, Wang X. Prognostic significance of in patients with chronic lymphocytic leukemia: A meta-analysis.. Annals of hematology. 2025. doi:10.1007/s00277-025-06499-4

2. Stilgenbauer S, Schnaiter A, Paschka P, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood. 2014. doi:10.1182/blood-2014-01-546150

3. Oscier D, Rose‐Zerilli M, Winkelmann N, et al. The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. Blood. 2012. doi:10.1182/blood-2012-05-429282

4. Zhang Y, Qian J, Gu C, Yang Y. Alternative splicing and cancer: a systematic review. Signal Transduction and Targeted Therapy. 2021. doi:10.1038/s41392-021-00486-7

5. Tao Y, Zhang Q, Wang H, Yang X, Mu H. Alternative splicing and related RNA binding proteins in human health and disease. Signal Transduction and Targeted Therapy. 2024. doi:10.1038/s41392-024-01734-2

6. Xie N, Shen G, Gao W, Huang Z, Huang C, Fu L. Neoantigens: promising targets for cancer therapy. Signal Transduction and Targeted Therapy. 2023. doi:10.1038/s41392-022-01270-x

7. Guièze R, Robbe P, Clifford R, et al. Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL. Blood. 2015. doi:10.1182/blood-2015-05-647578

8. Galanina N, Bejar R, Choi MY, et al. Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials. Cancers. 2018. doi:10.3390/cancers11010011

9. Sekrecki M, Sekrecka A, Lattupally R, et al. Oncogenic SF3B1 mutations alter the splicing of mRNA noncoding regions to induce a novel therapeutic vulnerability.. Blood. 2026. doi:10.1182/blood.2025029972